SCHEMBL13097152

SCHEMBL13097152

CNC(=O)c1cc(C)nc(OC)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
BAZ2B Q9UIF8 1/20 0.41
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
CTSA P10619 1/20 0.38
POLB P06746 3/20 0.38
GRM5 P41594 1/20 0.37
BRD4 O60885 2/20 0.37
PLK1 P53350 1/20 0.37
RBP4 P02753 1/20 0.36
HPGDS O60760 2/20 0.36
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36
LRRK2 Q5S007 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29082609 0.83 LMNA (0.67) LMNATDP1KDM4EKMT2ACTSA
SCHEMBL3521003 0.82 KDM4E (0.48) LMNATDP1KDM4EMEN1MAPT
SCHEMBL1179070 0.80 LMNA (0.68) LMNATDP1KDM4EMEN1KMT2A
SCHEMBL882673 0.80 LMNA (0.49) LMNATDP1KDM4EMEN1MAPT
SCHEMBL13086860 0.79 LMNA (0.41) LMNATDP1BAZ2BCTSABRD4
SCHEMBL12083266 0.77 BAZ2B (0.44) BAZ2BMAPTPOLBBRD4RBP4
SCHEMBL11925521 0.77 BAZ2B (0.44) LMNABAZ2BMEN1KMT2APOLB
SCHEMBL16572978 0.75 HSP90AB1 (0.50) BAZ2BKDM4EMAPTPOLBBRD4
SCHEMBL19448469 0.74 CTSA (0.46) LMNABAZ2BMAPTCTSAPOLB
SCHEMBL25208370 0.73 LMNA (0.42) LMNATDP1KDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100261679-A1 CSF-1R, Inhibitors, Compositions, and Methods of Use NOVARTIS AG (CH) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261679-A1 CSF-1R, Inhibitors, Compositions, and Methods of Use CSF1R, CSF3R, MSR1 LMNA 3953/4885TDP1 2301/4885BAZ2B 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.